Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Long-term Follow-up Study for Multiple Sclerosis Patients Who Have Completed the Alemtuzumab Extension Study (CAMMS03409)

NCT02255656 is registered in ClinicalTrials.gov with Genzyme, a Sanofi Company as lead sponsor.

NCT NCT02255656
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02255656 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Long-term Follow-up Study for Multiple Sclerosis Patients Who Have Completed the Alemtuzumab Extension Study (CAMMS03409)
Lead sponsor
Genzyme, a Sanofi Company
Phase
Phase 4
Overall status
Completed
Start date
January 7, 2015
Completion date
July 15, 2020
Enrollment
1,062 (actual)
Sites
131

Conditions

As the registry lists them; a condition with its own page is linked.

relapsing remitting multiple sclerosis